AstraZeneca (AZN.L) said Monday its ceralasertib-Imfinzi combination failed to improve survival in advanced lung cancer patients, sending shares down 1% as investors weighed the setback against the drugmaker’s broader oncology pipeline.
The trial failure represents a significant blow to AstraZeneca’s efforts to expand Imfinzi’s use beyond its current approved indications, potentially limiting revenue growth from one of its key cancer treatments.
Key Takeaways
- Phase III LATIFY trial missed primary survival endpoint
- 594 patients tested across 20+ countries showed no benefit
- No new safety concerns identified with drug combination
Market reaction & context
AstraZeneca shares fell 1% in London trading following the announcement, underperforming the broader FTSE 100 index 1. The decline was relatively modest compared to typical biotech reactions to major trial failures, reflecting the company’s diversified drug portfolio.
Imfinzi generated 3.5 billion in revenue for AstraZeneca in 2023, making it one of the company’s top-selling treatments. The drug is already approved for various lung cancer indications, but the failed combination trial limits potential expansion opportunities.
Trial details
The LATIFY Phase III trial evaluated 594 patients from more than 20 countries whose advanced lung cancer lacked targetable mutations 2. Patients had previously received chemotherapy and immunotherapy before entering the study.
The combination of experimental drug ceralasertib with Imfinzi (durvalumab) was tested against standard-of-care docetaxel chemotherapy. While the treatment showed no new safety concerns, it failed to demonstrate a statistically significant improvement in overall survival compared to the control arm 3.
Drug development context
Ceralasertib is an investigational ATR kinase inhibitor designed to target DNA damage repair pathways in cancer cells. AstraZeneca has been testing the drug in various combinations as part of its broader strategy to develop precision oncology treatments.
The failure comes as pharmaceutical companies face increasing pressure to demonstrate clear clinical benefits in late-stage trials, with regulators demanding robust evidence before approving new cancer treatments. Success rates for oncology drugs in Phase III trials typically range from 40% to 60%.
Company outlook
AstraZeneca continues to advance ceralasertib in other clinical trials across different cancer types and treatment combinations. The company’s oncology division remains a key growth driver, with multiple drugs in various stages of development.
Despite Monday’s setback, AstraZeneca received positive news on another front, with its Enhertu treatment winning FDA breakthrough therapy designation for a different cancer indication 4. This mixed bag of clinical results reflects the inherent risks and opportunities in pharmaceutical development.
Investor implications
The trial failure highlights the challenges facing large pharmaceutical companies as they seek to extend the commercial life of existing blockbuster drugs through new combinations and indications. While disappointing, the modest share price reaction suggests investors view this as a manageable setback within AstraZeneca’s broader development portfolio.
Analysts will likely focus on the company’s remaining pipeline assets and upcoming clinical readouts as they assess the long-term growth trajectory for AstraZeneca’s oncology franchise.
Not investment advice. For informational purposes only.
References
1Reuters (2025-12-22). “AstraZeneca’s ceralasertib-Imfinzi drug combo misses survival target”. Reuters. Retrieved December 22, 2025.
2AstraZeneca (2025-12-22). “Update on LATIFY Phase III trial of ceralasertib plus Imfinzi”. AstraZeneca. Retrieved December 22, 2025.
3Yahoo Finance (2025-12-22). “AstraZeneca’s ceralasertib-Imfinzi combo misses survival target”. Yahoo Finance. Retrieved December 22, 2025.
4TipRanks (2025-12-22). “Mixed Bag for AZN Stock: AstraZeneca’s Enhertu Wins FDA Breakthrough”. TipRanks. Retrieved December 22, 2025.